FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559547090> ?p ?o ?g. }

• W2559547090 abstract "Abstract The discovery of the activating V617F mutation in the JAK2 tyrosine kinase gene in patients with myloproliferative disorders (MPD) provides a major breakthrough in the understanding of the pathogenesis, proving clonality and securing diagnosis of these diseases. The JAK2 V617F allele is an acquired somatic disease allele that arises in hematopoietic progenitors and confers a selective growth advantage. The mutation has been traced to a primitive stem cell that is capable of erythroid and myeloid differentiation. The data for the potential involvement of the B and T lymphocytes with the JAK2V617F mutation are still inconsistent. We present the results from the study designed the evaluate the prevalence of the JAK2V617F mutation in MPDs patients in our population and to investigate whether MPD patients that carry the JAK2V617F mutation differ in clinical course and outcome from JAK2V617F negative MPD patients. The study group consisted of 64 living MPD patients diagnosed according to standard WHO criteria for diagnosis of MPD (26 patients were diagnosed as polycythemia vera (PV), 34 as essential thrombocythemia (ET), 6 as idiopatic myelofibrosis (MF) and 8 were classified as atypical MPD) with the median follow-up of 7,4 years. DNA samples were obtained from unfractionated blood samples and the frequency of V617F JAK2 mutation was analyzed by allele-specific PCR assay. The mutant allele burden in mutation positive samples was analyzed by DNA sequencing. Our results showed that the JAK2 V617F mutation was present in 79% of patients with PV (36% were homozygous for the mutation), 58% with ET (11% homozygous), 69% with MF (28% homozygous) and in 33% of patients with atypical MPD. The mutant JAK2V617F allele burden was greater than 95% in two PV patients, which in the presence of 27% lymphocytes in the peripheral blood of the patients indicate lymphocytes involvement with the mutation. The high frequency of observed homozygosity for JAK2V617F in our study group was probably due to the long disease duration (median follow-up 11,4 years) and favors the theory of a time dependent increase in clonal dominance. Correlations of clinical and laboratory features at diagnosis and subsequent follow-up, including incidence of thrombo-hemorrhagic events, disease transformation and survival of JAK2V617F-positive and JAK2V617F-negative patients did not reveal significant differences except for the incidence of thrombotic complications. The JAK2V617F positive group had a higher incidence of thrombotic complications (30%) compared with the JAK2-V617F-negative group (14%, P< 0.05). Although we observed a disparity in the incidence of the JAK2V617F mutation in different MPD entities in our population with respect to the expected frequency of JAK2V617F from the literature, our results confirm the diagnostic significance of the JAK2V617F mutation in MPDs and support the notion that patients with this mutation should be classified in a new entity of MPDs. Identification of homozygous JAK2V617F mutation in unfractionated blood samples in a substantial proportion of long term follow-up MPD patients, together with the identification of the mutant JAK2V617F allele burden greater than 95% in two PV patients, suggests that acquisition of the JAK2V617F mutation arises in early multilineage hematopoietic progenitors and warrants further investigation." @default.
• W2559547090 created "2016-12-08" @default.
• W2559547090 creator A5003097201 @default.
• W2559547090 creator A5005484305 @default.
• W2559547090 creator A5050546840 @default.
• W2559547090 creator A5074435079 @default.
• W2559547090 creator A5076787033 @default.
• W2559547090 creator A5079967189 @default.
• W2559547090 creator A5083385263 @default.
• W2559547090 date "2007-11-16" @default.
• W2559547090 modified "2023-09-30" @default.
• W2559547090 title "Identification of Homozygous JAK2V617F Mutation in Unfractioned Blood Samples in a Substantial Proportion of Myeloproliferative Disorders: Long Term Follow-Up Study." @default.
• W2559547090 doi "https://doi.org/10.1182/blood.v110.11.4644.4644" @default.
• W2559547090 hasPublicationYear "2007" @default.
• W2559547090 type Work @default.
• W2559547090 sameAs 2559547090 @default.
• W2559547090 citedByCount "0" @default.
• W2559547090 crossrefType "journal-article" @default.
• W2559547090 hasAuthorship W2559547090A5003097201 @default.
• W2559547090 hasAuthorship W2559547090A5005484305 @default.
• W2559547090 hasAuthorship W2559547090A5050546840 @default.
• W2559547090 hasAuthorship W2559547090A5074435079 @default.
• W2559547090 hasAuthorship W2559547090A5076787033 @default.
• W2559547090 hasAuthorship W2559547090A5079967189 @default.
• W2559547090 hasAuthorship W2559547090A5083385263 @default.
• W2559547090 hasConcept C104317684 @default.
• W2559547090 hasConcept C126322002 @default.
• W2559547090 hasConcept C180754005 @default.
• W2559547090 hasConcept C203014093 @default.
• W2559547090 hasConcept C2778837598 @default.
• W2559547090 hasConcept C2779282312 @default.
• W2559547090 hasConcept C2780007613 @default.
• W2559547090 hasConcept C2780076729 @default.
• W2559547090 hasConcept C2781057849 @default.
• W2559547090 hasConcept C2908647359 @default.
• W2559547090 hasConcept C2910274570 @default.
• W2559547090 hasConcept C501734568 @default.
• W2559547090 hasConcept C54355233 @default.
• W2559547090 hasConcept C71924100 @default.
• W2559547090 hasConcept C86803240 @default.
• W2559547090 hasConcept C90924648 @default.
• W2559547090 hasConcept C99454951 @default.
• W2559547090 hasConceptScore W2559547090C104317684 @default.
• W2559547090 hasConceptScore W2559547090C126322002 @default.
• W2559547090 hasConceptScore W2559547090C180754005 @default.
• W2559547090 hasConceptScore W2559547090C203014093 @default.
• W2559547090 hasConceptScore W2559547090C2778837598 @default.
• W2559547090 hasConceptScore W2559547090C2779282312 @default.
• W2559547090 hasConceptScore W2559547090C2780007613 @default.
• W2559547090 hasConceptScore W2559547090C2780076729 @default.
• W2559547090 hasConceptScore W2559547090C2781057849 @default.
• W2559547090 hasConceptScore W2559547090C2908647359 @default.
• W2559547090 hasConceptScore W2559547090C2910274570 @default.
• W2559547090 hasConceptScore W2559547090C501734568 @default.
• W2559547090 hasConceptScore W2559547090C54355233 @default.
• W2559547090 hasConceptScore W2559547090C71924100 @default.
• W2559547090 hasConceptScore W2559547090C86803240 @default.
• W2559547090 hasConceptScore W2559547090C90924648 @default.
• W2559547090 hasConceptScore W2559547090C99454951 @default.
• W2559547090 hasLocation W25595470901 @default.
• W2559547090 hasOpenAccess W2559547090 @default.
• W2559547090 hasPrimaryLocation W25595470901 @default.
• W2559547090 hasRelatedWork W2081429895 @default.
• W2559547090 hasRelatedWork W2098731025 @default.
• W2559547090 hasRelatedWork W2114735362 @default.
• W2559547090 hasRelatedWork W2125840023 @default.
• W2559547090 hasRelatedWork W2151320936 @default.
• W2559547090 hasRelatedWork W2525050062 @default.
• W2559547090 hasRelatedWork W2550481020 @default.
• W2559547090 hasRelatedWork W2557518604 @default.
• W2559547090 hasRelatedWork W3097321916 @default.
• W2559547090 hasRelatedWork W2376515172 @default.
• W2559547090 isParatext "false" @default.
• W2559547090 isRetracted "false" @default.
• W2559547090 magId "2559547090" @default.
• W2559547090 workType "article" @default.